We found that STING expression level is lower in “KDM5B high” samples than in “KDM5B low” samples from multiple human tumor types, including breast invasive carcinoma, bladder urothelial carcinoma, and ovarian serous cystadenocarcinoma (Fig 7A). This evidence concerns the gene STING1 and ovarian serous cystadenocarcinoma.